Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07314242) titled 'A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd
Condition:
COPD (Chronic Obstructive Pulmonary Disease)
Intervention:
Drug: Hemay005 tablets
Drug: Roflumilast Oral Tablet
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: January 1, 2026
Targe...